research Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women
Evaluate and manage androgen excess in women with a systematic approach, considering both physical and psychological impacts.
Search
forResearch
5 / 1000+ results
research Clinical Impact of Molecular Diagnostics in Endocrinology
This review discusses molecular testing for endocrine diseases, highlighting its diagnostic benefits and potential for prevention, particularly in conditions like multiple endocrine neoplasia type 2 and adrenogenital syndrome, but reports no new clinical results.
research European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
These guidelines recommend testing thyroid function in patients with obesity due to common hypothyroidism, and highlight that weight loss is crucial for addressing hormonal imbalances, with only modest weight loss benefits from treating endocrine disorders.
research American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hyperandrogenic Disorders
This article provides diagnosis and treatment guidelines for hyperandrogenic disorders in women but reports no new clinical results; it offers a summary of accepted scientific information and suggestions for clinical practice.
research American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1
This review discusses the diagnostic criteria and management strategies for Polycystic Ovary Syndrome (PCOS) and highlights the need for comprehensive clinical assessment, but does not report new clinical findings.
Community Join
5 / 1000+ resultscommunity I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community Finasteride/dutasteride/etcetera. Clinical opinions of 1 GP and 1 leading urologist + links to reliable studies.
Finasteride is effective for treating male pattern baldness (MPB) with minimal side effects, and topical finasteride is similarly effective. Dutasteride is also effective but less understood, and Minoxidil is less effective than Finasteride.
community Interesting new publication suggesting that MPB should be assessed as a early warning sign for type-2 diabetes.
Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.
community M25: Getting way too many DMs, so let’s do this here! AMA about Male Pattern Baldness, Hair Loss, and Products (100% Science-Backed )
Finasteride, dutasteride, and minoxidil are discussed as treatments for male pattern baldness. Finasteride and dutasteride are effective DHT blockers, while minoxidil is necessary for regrowth but must be used consistently.
community Finasteride does deplete important nuero-active steroids
Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.
Learn
6 / 801 results- Are there clinical studies showing that KY19382 can regrow hair in androgenic alopecia? No clinical studies have proven KY19382 regrows hair in androgenic alopecia.
- What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth? No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.
- Are there any clinical studies supporting follistatin as a hair loss treatment? There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.
- What types of hair loss conditions are most commonly associated with tofacitinib use in clinical settings? Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.
- When will GT20029 be commercially available, and are there any clinical trials on its use? GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn KY19382
learn SCUBE3
learn Follistatin
learn Tofacitinib
learn GT20029
Clinics
2 / 2 results
Experts
— no results